mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022.
Euro Surveill
; 27(20)2022 05.
Article
in English
| MEDLINE | ID: covidwho-1862541
ABSTRACT
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
Topics:
Vaccines
/
Variants
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
1560-7917.ES.2022.27.20.2200350
Similar
MEDLINE
...
LILACS
LIS